Til Menge

3.7k total citations
46 papers, 1.9k citations indexed

About

Til Menge is a scholar working on Pathology and Forensic Medicine, Rheumatology and Neurology. According to data from OpenAlex, Til Menge has authored 46 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pathology and Forensic Medicine, 16 papers in Rheumatology and 15 papers in Neurology. Recurrent topics in Til Menge's work include Multiple Sclerosis Research Studies (31 papers), Peripheral Neuropathies and Disorders (14 papers) and Systemic Lupus Erythematosus Research (11 papers). Til Menge is often cited by papers focused on Multiple Sclerosis Research Studies (31 papers), Peripheral Neuropathies and Disorders (14 papers) and Systemic Lupus Erythematosus Research (11 papers). Til Menge collaborates with scholars based in Germany, United States and Switzerland. Til Menge's co-authors include Olaf Stüve, Bernd C. Kieseier, Bernhard Hemmer, Hans-Peter Hartung, Claude P. Genain, H.‐Christian von Büdingen, Patrice H. Lalive, Stefan Nessler, Heinz Wiendl and Hans‐Peter Hartung and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature reviews. Neuroscience and Neurology.

In The Last Decade

Til Menge

42 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Til Menge Germany 26 1.0k 714 445 367 331 46 1.9k
Oliver Neuhaus Germany 22 995 1.0× 484 0.7× 788 1.8× 333 0.9× 333 1.0× 52 2.0k
José C. Álvarez‐Cermeño Spain 27 1.4k 1.4× 735 1.0× 569 1.3× 648 1.8× 470 1.4× 87 2.3k
Joachim Burman Sweden 28 1.6k 1.6× 669 0.9× 686 1.5× 507 1.4× 276 0.8× 111 2.8k
Hirofumi Ochi Japan 24 654 0.6× 468 0.7× 649 1.5× 323 0.9× 303 0.9× 89 1.8k
John S. Tzartos Greece 15 788 0.8× 340 0.5× 955 2.1× 323 0.9× 231 0.7× 69 2.0k
M. Söderström Sweden 29 1.1k 1.1× 452 0.6× 975 2.2× 275 0.7× 355 1.1× 55 2.4k
Sara J. Piddlesden United Kingdom 21 870 0.9× 564 0.8× 1.1k 2.5× 424 1.2× 278 0.8× 30 2.2k
Mónica Marta United Kingdom 20 1.0k 1.0× 368 0.5× 761 1.7× 307 0.8× 266 0.8× 66 1.9k
Mark Wing United Kingdom 29 929 0.9× 339 0.5× 1.2k 2.6× 645 1.8× 260 0.8× 47 3.0k
Tatiana Plavina United States 22 1.4k 1.4× 444 0.6× 480 1.1× 350 1.0× 210 0.6× 46 2.6k

Countries citing papers authored by Til Menge

Since Specialization
Citations

This map shows the geographic impact of Til Menge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Til Menge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Til Menge more than expected).

Fields of papers citing papers by Til Menge

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Til Menge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Til Menge. The network helps show where Til Menge may publish in the future.

Co-authorship network of co-authors of Til Menge

This figure shows the co-authorship network connecting the top 25 collaborators of Til Menge. A scholar is included among the top collaborators of Til Menge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Til Menge. Til Menge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Menge, Til. (2024). Hocheffektive Therapien absetzen?. InFo Neurologie + Psychiatrie. 26(10). 20–21.
2.
Rubbert, Christian, Marius Kaschner, Nadja Kairies‐Schwarz, et al.. (2024). Prehospital telemedicine support for urban stroke care: Analysis of current state of care and conceptualization. BMC Emergency Medicine. 24(1). 224–224.
3.
Meuth, Sven G., et al.. (2023). Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease. CNS Drugs. 37(1). 69–92. 16 indexed citations
4.
Schwenkenbecher, Philipp, Thomas Skripuletz, Peter Lange, et al.. (2021). Intrathecal Antibody Production Against Epstein-Barr, Herpes Simplex, and Other Neurotropic Viruses in Autoimmune Encephalitis. Neurology Neuroimmunology & Neuroinflammation. 8(6). 20 indexed citations
5.
Kramer, Daniel, Poul Erik Jensen, Malin Ryner, et al.. (2017). Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta. Frontiers in Neurology. 8. 305–305. 7 indexed citations
6.
Menge, Til, Divyanshu Dubey, Clemens Warnke, Hans-Peter Hartung, & Olaf Stüve. (2016). Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Review of Neurotherapeutics. 16(10). 1131–1139. 15 indexed citations
7.
Ingwersen, Jens, Til Menge, Britta Wingerath, et al.. (2014). Natalizumab restores aberrant miRNAexpression profile in multiple sclerosis and reveals a critical role for miR‐20b. Annals of Clinical and Translational Neurology. 2(1). 43–55. 68 indexed citations
8.
Warnke, Clemens, Til Menge, Hans‐Peter Hartung, et al.. (2010). Natalizumab and Progressive Multifocal Leukoencephalopathy. Archives of Neurology. 67(8). 923–30. 86 indexed citations
9.
Wolf, Christian, Til Menge, Gerd Meyer zu Hörste, et al.. (2010). Natalizumab Treatment in a Patient With Chronic Inflammatory Demyelinating Polyneuropathy. Archives of Neurology. 67(7). 881–3. 35 indexed citations
10.
Stüve, Olaf, Verena I. Leussink, Bernhard Hemmer, et al.. (2009). Long-term B-Lymphocyte Depletion With Rituximab in Patients With Relapsing-Remitting Multiple Sclerosis. Archives of Neurology. 66(2). 259–61. 37 indexed citations
11.
Menge, Til, Martin S. Weber, Bernhard Hemmer, et al.. (2008). Disease-Modifying Agents for Multiple Sclerosis. Drugs. 68(17). 2445–2468. 49 indexed citations
12.
Stüve, Olaf, Jeffrey L. Bennett, Bernhard Hemmer, et al.. (2008). Pharmacological Treatment of Early Multiple Sclerosis. Drugs. 68(1). 73–83. 37 indexed citations
13.
Menge, Til, H.‐Christian von Büdingen, Patrice H. Lalive, & Claude P. Genain. (2007). Relevant antibody subsets against MOG recognize conformational epitopes exclusively exposed in solid‐phase ELISA. European Journal of Immunology. 37(11). 3229–3239. 31 indexed citations
14.
Menge, Til, Bernd C. Kieseier, Stefan Nessler, et al.. (2007). Acute disseminated encephalomyelitis: an acute hit against the brain. Current Opinion in Neurology. 20(3). 247–254. 97 indexed citations
15.
Dazin, Paul, et al.. (2006). Apoptotic effects of Human Herpesvirus-6A on glia and neurons as potential triggers for central nervous system autoimmunity. Journal of Clinical Virology. 37. S11–S16. 24 indexed citations
16.
Menge, Til, Patrice H. Lalive, H.‐Christian von Büdingen, et al.. (2005). Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. Journal of Allergy and Clinical Immunology. 116(2). 453–459. 62 indexed citations
17.
Menge, Til, Hans-Peter Hartung, & Olaf Stüve. (2005). Statins — a cure-all for the brain?. Nature reviews. Neuroscience. 6(4). 325–331. 80 indexed citations
18.
Menge, Til, Bernhard Hemmer, Stefan Nessler, et al.. (2005). Acute Disseminated Encephalomyelitis. Archives of Neurology. 62(11). 1673–1673. 249 indexed citations
19.
Jander, Sebastian, Simona Bussini, Frank Bosse, et al.. (2001). Osteopontin: A novel axon‐regulated Schwann cell gene. Journal of Neuroscience Research. 67(2). 156–166. 32 indexed citations
20.
Menge, Til, Tobias Neumann‐Haefelin, Hans-Jürgen von Giesen, & Gabriele Arendt. (2000). Progressive Stroke in an HIV-1-Positive Patient under Protease Inhibitors. European Neurology. 44(4). 252–254. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Oliver Neuhaus Breakdown of academic impact, for papers by José C. Álvarez‐Cermeño Breakdown of academic impact, for papers by Joachim Burman Breakdown of academic impact, for papers by Hirofumi Ochi Breakdown of academic impact, for papers by John S. Tzartos Breakdown of academic impact, for papers by M. Söderström Breakdown of academic impact, for papers by Sara J. Piddlesden Breakdown of academic impact, for papers by Mónica Marta Breakdown of academic impact, for papers by Mark Wing Breakdown of academic impact, for papers by Tatiana Plavina
Rankless by CCL
2026